Emory University, a private research institution in Atlanta, Georgia, has been awarded a $452,549 Project Grant by the National Cancer Institute (NCI) under the Cancer Treatment Research Federal Grant Program (CFDA 93.395). The funding will support a 5-year research project to comprehensively characterize and target the intrinsic and extrinsic molecular features of MYC-driven osteosarcoma, the most common bone tumor in pediatric patients. The project aims to define the unique intrinsic molecular signatures and extrinsic tumor microenvironment characteristics of MYC-amplified osteosarcoma, and develop novel combinatorial therapeutic approaches to enhance targeted treatment efficacy for this high-risk patient subgroup. The long-term goal is to change the treatment paradigm for osteosarcoma by enabling early risk stratification and upfront targeted therapy to improve patient outcomes.
Generated 3/18/25, 5:12 AM